Vertex Pharmaceuticals Stock: Why Casgevy’s Pediatric Label Expansion Matters
Vertex Pharmaceuticals stock has drawn renewed market scrutiny after the US Food and Drug Administration expanded the approval of Casgevy, a CRISPR/Cas9 gene therapy, to children aged 2 and older ... Read More